These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 4792890)

  • 1. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
    Jones DG; Lenman JA; Robertson MA; Turnbull MJ
    Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
    [No Abstract]   [Full Text] [Related]  

  • 3. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
    Jones DG; Turnbull MJ; Lenman JA; Robertson MA
    J Neurol Sci; 1972 Nov; 17(3):245-53. PubMed ID: 4653961
    [No Abstract]   [Full Text] [Related]  

  • 5. Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
    Lenman JA; Turnbull MJ; Reid A; Fleming AM
    J Neurol Sci; 1977 Jun; 32(2):219-25. PubMed ID: 874521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
    Dziedzic SW; Dziedzic LB; Gitlow SE
    J Lab Clin Med; 1973 Nov; 82(5):829-35. PubMed ID: 4746822
    [No Abstract]   [Full Text] [Related]  

  • 7. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 8. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic patterns and clinical response to levedopa therapy in Parkinson's disease.
    Messiha FS; Knopp W
    Clin Pharmacol Ther; 1973; 14(4):565-71. PubMed ID: 4541856
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 12. [Simultaneous evaluation by gas chromatography of urinary acids: homovanillic, vanilmandelic, indoleacetic and 5 hydroxyindoleacetic].
    Ruíz-González MC; Arranz MI
    Rev Clin Esp; 1980 Aug 15-31; 158(3-4):139-43. PubMed ID: 6159668
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of clozapine on the excretion of 3-methoxy-4-hydroxy-phenylglycol, homovanillic acid and 5-hydroxy-indole acetic acid in urine and cerebrospinal fluid].
    Ackenheil M; Beckmann H; Hoffmann G; Markianos E; Nyström I; Raese J
    Arzneimittelforschung; 1974 Jul; 24(7):984-7. PubMed ID: 4408052
    [No Abstract]   [Full Text] [Related]  

  • 14. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes].
    Kluzer G; Lampo B
    Minerva Med; 1971 Oct; 62(82):4013-4. PubMed ID: 5125067
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prolonged treatment of Parkinson's disease with amantadine and L-Dopa].
    Fieschi C; Casacchia M; Nardini M; Reitano N
    Minerva Med; 1971 Oct; 62(82):4040-2. PubMed ID: 5125075
    [No Abstract]   [Full Text] [Related]  

  • 16. [Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
    Raspa EG; Paciaroni E; Saccomanno G
    Minerva Med; 1971 Oct; 62(82):4031-5. PubMed ID: 5125073
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoamine metabolism during chronic benzodiazepine treatment and withdrawal.
    Petursson H; Bond PA; Smith B; Lader MH
    Biol Psychiatry; 1983 Feb; 18(2):207-13. PubMed ID: 6187380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amantadine in the treatment of transitory hypokinesia in patients with parkinsonism during therapy with L-Dopa].
    De Divitiis E; D'Andrea F; Signorelli CD; Cerillo A
    Minerva Med; 1971 Oct; 62(82):4007-8. PubMed ID: 5125065
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of parkinsonism with L-Dopa and amantadine.
    Green J
    J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813
    [No Abstract]   [Full Text] [Related]  

  • 20. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.